CNR2 and glioblastoma: For 10 compounds, the reduction in viability was more marked in neuroblastoma cells (NB-PDX2, NB-PDX3, SK-N-BE(2) and SK-N-SH) when compared with glioblastoma reference cells (U3013MG), the difference being largest for the CNR2 modulator GW405833 (Fig. 5a).